Drug Pipeline

Ris-Rez Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12

Active Studies

Recruiting

Phase 3

Top Sponsors

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-05-28	NCT07099898 A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)	Trial sites expanded: 114 -> 120 locations

New Trial Filings, Last 30 Days

First Posted	Trial	Phase	Status
2026-05-22	NCT07602777 A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With…	Phase 1/2	Not Yet Recruiting
2026-05-22	NCT07602855 A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With…	Phase 1/2	Not Yet Recruiting

Active Studies by Phase

Phase 3

Phase 1/2

Phase 1

Active Trials

NCT ID	Title	Condition	Status
Phase 3
NCT07099898	A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)	Neoplasms, Lung	Recruiting
Phase 1/2
NCT07602777	A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With…	Sarcoma	Not Yet Recruiting
NCT07602855	A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With…	Solid Tumors	Not Yet Recruiting
Phase 1
NCT06551142	A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)	Neoplasms	Recruiting

Sponsors Running Ris-Rez Trials

GlaxoSmithKline (4)

Disease Areas

Sarcoma (1)

Get alerts when Ris-Rez trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.